Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
出版年份 2019 全文链接
标题
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
作者
关键词
-
出版物
CNS SPECTRUMS
Volume 24, Issue S1, Pages 38-69
出版商
Cambridge University Press (CUP)
发表日期
2019-09-04
DOI
10.1017/s109285291900124x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials
- (2019) Davy Vancampfort et al. World Psychiatry
- Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia
- (2019) Hannah E. Brown et al. JAMA Psychiatry
- Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia
- (2019) Istvan Bitter et al. NEUROPSYCHOPHARMACOLOGY
- A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
- (2019) C. Michael White JOURNAL OF CLINICAL PHARMACOLOGY
- 26 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients with Acute Exacerbation of Schizophrenia
- (2019) Steven G Potkin et al. CNS SPECTRUMS
- Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
- (2019) William F. Martin et al. AMERICAN JOURNAL OF PSYCHIATRY
- Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
- (2019) Taishiro Kishimoto et al. World Psychiatry
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- F197. Aripiprazole Lauroxil NanoCrystal® Dispersion: A Potential 1-Day Initiation Regimen for Long-Acting Aripiprazole Lauroxil
- (2018) David Walling et al. BIOLOGICAL PSYCHIATRY
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
- (2018) F. Markus Leweke et al. CNS DRUGS
- Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
- (2018) Marjie L. Hard et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases
- (2018) Michael D. Schwartz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms
- (2018) Richard S. E. Keefe et al. JOURNAL OF CLINICAL PSYCHIATRY
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
- (2018) Kimberly Vanover et al. SCHIZOPHRENIA BULLETIN
- What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
- (2018) Christoph U. Correll et al. World Psychiatry
- Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
- (2018) Marco Solmi et al. Drug Design Development and Therapy
- Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
- (2018) Stefano Espinoza et al. Frontiers in Pharmacology
- Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial
- (2018) Xiujuan Wang et al. PSYCHIATRY RESEARCH
- A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
- (2018) Thomas A. Macek et al. SCHIZOPHRENIA RESEARCH
- Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
- (2018) Maren Carbon et al. World Psychiatry
- Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia
- (2018) Lei Sun et al. CLINICAL THERAPEUTICS
- Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study
- (2017) Viktoria Moschetti et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
- (2017) Albert Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use
- (2017) Maren Carbon et al. JOURNAL OF CLINICAL PSYCHIATRY
- Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies
- (2017) Taishiro Kishimoto et al. SCHIZOPHRENIA BULLETIN
- Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
- (2017) Christoph U. Correll et al. World Psychiatry
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia
- (2017) Christoph U. Correll et al. JAMA Psychiatry
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Chieh-Hsin Lin et al. BIOLOGICAL PSYCHIATRY
- A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
- (2017) Bernard L. Silverman et al. SCHIZOPHRENIA RESEARCH
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- The dopamine D3 receptor, a quarter century later
- (2016) Pierre Sokoloff et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
- (2016) Ricardo P. Garay et al. EXPERT OPINION ON PHARMACOTHERAPY
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
- (2016) Christoph U. Correll et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia
- (2016) Azmi F. Nasser et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms
- (2016) Kazunori Suzuki et al. NEUROPSYCHOPHARMACOLOGY
- The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial
- (2016) J. M. Stone et al. PSYCHOLOGICAL MEDICINE
- Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
- (2016) J. P. Maia-de-Oliveira et al. PSYCHOLOGICAL MEDICINE
- Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics
- (2016) Fuminari Misawa et al. SCHIZOPHRENIA RESEARCH
- Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study
- (2016) John J. Isitt et al. SCHIZOPHRENIA RESEARCH
- Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
- (2016) Davy Vancampfort et al. World Psychiatry
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
- (2015) Jose Crippa et al. CNS & Neurological Disorders-Drug Targets
- Ambiguous findings concerning potential advantages of depot antipsychotics
- (2015) Peter M. Haddad et al. CURRENT OPINION IN PSYCHIATRY
- Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
- (2015) Richard SE Keefe et al. NEUROPSYCHOPHARMACOLOGY
- Molecular Targets of Cannabidiol in Neurological Disorders
- (2015) Clementino Ibeas Bih et al. Neurotherapeutics
- Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
- (2015) Christoph U. Correll et al. World Psychiatry
- Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
- (2015) Davy Vancampfort et al. World Psychiatry
- Schizophrenia
- (2015) Nature Reviews Disease Primers
- Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment
- (2014) Celine M. Laffont et al. CLINICAL PHARMACOKINETICS
- Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
- (2014) Maren Carbon et al. CNS SPECTRUMS
- Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
- (2014) Mark J. Millan et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Emerging drugs for schizophrenia: an update
- (2014) Luisa-Sophie Köster et al. EXPERT OPINION ON EMERGING DRUGS
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
- (2013) Silvia Sacchi et al. CURRENT PHARMACEUTICAL DESIGN
- Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
- (2013) Kenji Hashimoto et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry
- (2013) John M. Kane et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone
- (2013) R. Gomeni et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness
- (2013) Christoph U. Correll JOURNAL OF CLINICAL PSYCHIATRY
- Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia
- (2013) Taishiro Kishimoto et al. JOURNAL OF CLINICAL PSYCHIATRY
- Termination of Clozapine Treatment Due to Medical Reasons
- (2013) Jimmi Nielsen et al. JOURNAL OF CLINICAL PSYCHIATRY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
- (2013) John M. Kane et al. World Psychiatry
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside
- (2013) Jaime E. C. Hallak et al. JAMA Psychiatry
- A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
- (2012) Marco DiBonaventura et al. BMC Psychiatry
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
- (2012) Joshua A Salomon et al. LANCET
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Christopher J L Murray et al. LANCET
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Theo Vos et al. LANCET
- A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Stephen S Lim et al. LANCET
- A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight
- (2012) F G Revel et al. MOLECULAR PSYCHIATRY
- Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials
- (2012) T. Kishimoto et al. SCHIZOPHRENIA BULLETIN
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population
- (2012) Sergey N Mosolov et al. Annals of General Psychiatry
- Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
- (2011) T Kishimoto et al. MOLECULAR PSYCHIATRY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Rethinking schizophrenia
- (2010) Thomas R. Insel NATURE
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Syntheses of novel high affinity ligands for opioid receptors
- (2009) Mark P. Wentland et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
- (2009) Christoph U. Correll JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
- (2009) S. M. Grauer et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Back to the Future
- (2008) Patrick D. McGorry et al. ARCHIVES OF GENERAL PSYCHIATRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now